UK sees launch of Novartis COPD drug Onbrez Breezhaler, which Scotland clears for NHS use
Swiss drug major Novartis today launched its Onbrez Breezhaler (indacaterol), the first 24-hour long-acting beta agonist (LABA) for the treatment of Chronic Obstructive Pulmonary Disease (COPD) in adults, in the UK.
This once daily medication is the first new treatment for COPD available in the UK for eight years. Indacaterol offers rapid and sustained improvement in lung function over 24 hours and clinically significant improvement in breathlessness at six months versus placebo, the company noted.
Drug is 'statistically superior,' says SMC
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze